Healthcare Professionals
Presentations, Abstracts, and Publications
Corvia Medical is committed to the continued publication of clinical data supporting the benefits of atrial shunting to reduce elevated left atrial pressure for the treatment of symptomatic heart failure.
Presentations & Abstracts
Patient Selection Considerations for Trials of Interatrial Shunts
S. Shah
Presented at THT 2024
Longitudinal Echocardiographic Changes in REDUCE-LAP II
D. Kaye
Presented at THT 2024
Short-term Atrial Shunt Device-Induced Changes in Cardiac Structure/Function and Risk of Subsequent Heart Failure Events: Findings from the REDUCE-LAP HF II
D. Kaye
Presented at THT 2024
Long-Term Effects of Atrial Shunt Device on Cardiac Structure and Function in HFpEF and HFmrEF: Results from the REDUCE LAP-HFII Randomized Clinical Trial
S. Shah
Presented at HFSA 2023
Two-year outcomes after implantation of an atrial shunt in patients with heart failure and preserved or mildly reduced ejection fraction: Results from the REDUCE LAP-HF II trial
F. Gustafsson
Presented at ESC HF 2023
Implications of Left Atrial Hypertension at Rest and Exercise
S. Litwin
Presented at THT 2023
Obesity in HFpEF: Insights from the REDUCE LAP-HF II Trial
S. Litwin
Presented at THT 2023
What (Else) Have We Learned From REDUCE-LAP II?
S. Shah
Presented at TVT 2022
Exercise PVR: A Key Predictor of Benefit of Atrial Shunt Therapy in HFpEF?
S. Shah
Presented at TVT 2022
AF and Pacemakers in REDUCE LAP-HF II
M. Petrie
Presented at ESC Heart Failure 2022
Sex Differences in REDUCE LAP-HF II (Poster)
C. Lam
Presented at ESC Heart Failure 2022
Late Breaking Clinical Trials II – REDUCE LAP-HF II
G. Hasenfuß
Presented at DGK 2022
Transcatheter Interatrial Shunt for Treatment of Heart Failure
D. Burkoff
Presented at CRT 2022
Latent Pulmonary Vascular Disease Alters the Response to Atrial Shunt Device Treatment: A Post Hoc Analysis from REDUCE LAP-HF II
B. Borlaug
Presented at THT 2022
REDUCE LAP-HF II Pivotal Trial: Primary Results
S. Shah
Presented at THT 2022
Dresdner Erfahrungen mit dem atrialen Shunt-Therapie
F. Woitek
Presented at DGK 2021
Multizentrische klinische Ergebnisse und laufende klinische Studien
T. Siedler
Presented at DGK 2021
Pathophysiologie und Konzept der Senkung des Füllungsdrucks
P. Lurz
Presented at DGK 2021
Berliner Erfahrungen mit der REDUCE LAP-HF II Studie und mit der Post Market Studie
S. Winkler
Presented at DKG 2020
Corvia Medical IASD Clinical Results
M. Petrie, presented by Dr. Burkhoff
Presented at D-HF 2019
The importance of exercise hemodynamics in HF patient selection/device evaluation
D. Burkhoff
Presented at DGK 2019
Corvia Medical InterAtrial Shunt Device (IASD) for Heart Failure with Preserved Ejection Fraction
S. Lilly
Presented at TCT 2019
Inter-Atrial Shunts for Pulmonary Hypertension: Group I and Group II
D. Burkhoff
Presented at TCT 2019
Continuous Inter-Atrial shunting: Latest Clinical Insights
D. Burkhoff
Presented at EuroPCR 2019
Interatrial shunts; Corvia
T. Feldman
Presented at TCT 2018
Left atrial decompression in chronic heart failure: why, when, and to what extent?
D. Burkhoff
Presented at EuroPCR 2018
IASD for chronic heart failure: Clinical experience & latest evidence with continuous interatrial shunting
T. Feldman
Presented at EuroPCR 2018
Left atrial decompression to treat heart failure
G. Hasenfuß
Presented at ESC 2018
REDUCE LAP HF 2 year Outcomes
David Kaye
Presented at ESC 2018
A Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure With Preserved or Mid-Range Ejection Fraction: Corvia Medical
Ted Feldman
Presented at ESC 2018
Inter-Atrial Shunt Device: Corvia Medical
Ted Feldman
Presented at TCT 2017
How could interatrial shunting be beneficial in heart failure and pulmonary hypertension?
Daniel Burkhoff
Presented at D-HF 2017
Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure: Results From the REDUCE LAP-HF I Randomized Control Trial
Sanjiv J. Shah on behalf of the REDUCE LAP-HF investigators.
Presented at AHA 2017
Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial
David M. Kaye on behalf of the REDUCE LAP HF investigators.
Presented at AHA 2016
Initial Six Month Results of a Novel Inter-atrial Shunt Therapy for Heart Failure with Preserved Ejection Fraction
Kaye D, Malek F, Gustafsson F, et al.
Presented at ACC 2014
Publications
Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial
Patel RB, Silvestry FE, Komtebedde J, et al. JAMA Cardiol. Published online April 17, 2024. doi:10.1001/jamacardio.2024.0520
Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial.
Litwin SE, Komtebedde J, Seidler T, et al. Eur J Heart Fail. 2023 Nov 21. doi: 10.1002/ejhf.3092. Epub ahead of print.
Atrial Fibrillation Burden and Atrial Shunt Therapy in Heart Failure With Preserved Ejection Fraction.
Patel RB, Reddy VY, Komtebedde J, et al. JACC Heart Fail. 2023;S2213-1779(23)00298-6.
Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction.
Litwin SE, Komtebedde J, Hu M, et al. JACC Heart Fail. 2023;11(8 Pt 2):1103-1117.
Update on Atrial Shunt Therapy for Treatment of Heart Failure.
Litwin SE, Borlaug BA, Komtebedde J, Shah SJ. Struct Heart. 2022;6(6):100090.
Long-term follow-up of a patient undergoing interatrial shunt device implantation for treatment of heart failure with a preserved ejection fraction.
Dujka L, Neužil P, Reddy V, et al. J Int Med Res. 2022 May;50(5):3000605221098178. doi: 10.1177/03000605221098178.
Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.
Borlaug, BA, Blair, J, Bergmann, MW et al. Circulation. 2022;10.1161/CIRCULATIONAHA.122.059486.
Atrial Shunt Device for Heart Failure with Preserved and Mildly Reduced Ejection Fraction (REDUCE LAP-HF II): A Randomised, Multicentre, Blinded, Sham-Controlled Trial.
Shah SJ, Borlaug, BA, Chung, ES et al. Lancet. 2022;399(10330):1130-1140.
Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction.
Deis T, Wolsk E, Mujkanovic J, et al. ESC Heart Fail. 2022;9(1):186-195.
Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction.
Wolsk E, Kaye DM, Komtebedde J, et al. Eur J Heart Fail. 2021;23(5):754-764.
Double Transseptal Access for Atrial Fibrillation Ablation in the Presence of Investigational Interatrial Shunt Device.
Guandalini GS, Mazurek JA, Dixit S. JACC Case Rep. 2020 Dec 23;3(1):136-140. doi: 10.1016/j.jaccas.2020.09.056.
Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure
Griffin JM, Borlaug BA, Komtebedde J, et al. J Am Heart Assoc. 2020;9:e016760.
Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II)
Berry N, Mauri L, Feldman T,. et al. Am Heart J, 2020; 226:222-31.
Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial)
Hanff TC, Kaye DM, Hayward CS, et al. Am J Cardiol. 2019 Dec 15;124(12):1912-1917.
Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure with Preserved Ejection Fraction
Obokata M, Reddy YNV, Shah SJ, et al. JACC 2019 Nov 26:74(21):2539-50.
Heart Failure With Preserved Ejection Fraction In Perspective
Pfeffer MA, Shah AM, Borlaug BA. Circ Res. 2019;124(11):1598-1617.
Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction.
Wolsk E, Kaye D, Komtebedde J, et al. JACC Heart Fail. 2019;7(4):321-332.
Impact of an Interatrial Shunt Device on Survival and Heart Failure Hospitalizations in Patients with Preserved Ejection Fraction
Kaye DM, Petrie MC, McKenzie S, et al. ESC Heart Fail. 2019 Feb; 6(1): 62-69.
One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP HF I) Trial
Shah SJ, Feldman T, Ricciardi MJ, et al. JAMA Cardiol. 2018 Oct 1;3(10):968-977.
Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction
Wolsk E, Kaye D, Borlaug BA, et al. Eur J Heart Fail. 2018 Apr;20(4):715-722.
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure] A Phase 2, Randomized, Sham-Controlled Trial
Feldman T, Mauri L, Kahwash R, et al. Circulation. 2018 Jan 23;137(4):364-375.
One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction
Kaye DM, Hasenfuß G, Neuzil P, et al. Circ Heart Fail. 2016 Dec; 9(12).
Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I)
Feldman T, Komtebedde J, Burkhoff D, et al. Circ Heart Fail. 2016 Jul;9(7). pii: e003025.
Left-to-right atrial shunting: new hope for heart failure?
Rossignol P, Zannad F. Lancet. 2016 Mar 26; 387(10025): 1253-5.
A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicenter, open label, single-arm, phase 1 trial
Hasenfuß G, Hayward C, Burkhoff D, et al. Lancet 2016; 387: 1298–304.
Rationale and Design of the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (Reduce LAP-HF) Trial
Hasenfuβ G, Gustafsson F, Kaye D, et al. J Card Fail 2015; 21(7): 594-600.
Clinical Outcome of Transcatheter Treatment of Heart Failure with Preserved or Mildly Reduced Ejection Fraction Using a Novel Implant
Malek F, Neuzil P, Gustafsson F, et al. International Journal of Cardiology 2015; 187:227–28.
Transcatheter Treatment of Heart Failure with Preserved or Mildly Reduced Ejection Fraction Using a Novel Interatrial Implant to Lower Left Atrial Pressure
Søndergaard L, Reddy V, Kaye D, et al. Eur J Heart Failure 2014; 16:796-8
Effects of an Interatrial Shunt on Rest and Exercise Hemodynamics: Results of a Computer Simulation in Heart Failure
Kaye D, Shah SJ, Borlaug BA, et al. Journal of Cardiac Failure. 2014;20(3):212-21.